Literature DB >> 2610821

Evidence for common alterations in cerebral glucose metabolism in major affective disorders and schizophrenia.

R M Cohen1, W E Semple, M Gross, T E Nordahl, A C King, D Pickar, R M Post.   

Abstract

Regional glucose metabolic rates were measured in affectively disordered patients during the performance of auditory discrimination. Those regions previously observed as abnormal in schizophrenia were examined to see if similar alterations might be associated with affective disorder. The abnormalities observed in the mid-prefrontal cortex, an area that appears to be an important biologic determinant of the sustained attention required of subjects in this task, are similar to those previously observed in schizophrenia. Moreover, the abnormalities do not appear to relate directly to symptomatology or the subject's performance. The authors discuss the possibility that this abnormality may reflect dysfunction in the integrating component of the attention network critical for the maintenance of goal-directed behavior and thus represent a psychosis vulnerability factor in some patients.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2610821     DOI: 10.1016/0893-133x(89)90028-6

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  12 in total

Review 1.  Biology and recent brain imaging studies in affective psychoses.

Authors:  P W Wang; T A Ketter
Journal:  Curr Psychiatry Rep       Date:  2000-08       Impact factor: 5.285

2.  Sleep deprivation increases dorsal nexus connectivity to the dorsolateral prefrontal cortex in humans.

Authors:  Oliver G Bosch; Julia S Rihm; Milan Scheidegger; Hans-Peter Landolt; Philipp Stämpfli; Janis Brakowski; Fabrizio Esposito; Björn Rasch; Erich Seifritz
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-11       Impact factor: 11.205

3.  The schizophrenias, the neuroses and the covered wagon; a critical review.

Authors:  C Raymond Lake; Nathaniel Hurwitz
Journal:  Neuropsychiatr Dis Treat       Date:  2007-02       Impact factor: 2.570

4.  Decreased prefrontal, anterior cingulate, insula, and ventral striatal metabolism in medication-free depressed outpatients with bipolar disorder.

Authors:  John O Brooks; Po W Wang; Julie C Bonner; Allyson C Rosen; Jennifer C Hoblyn; Shelley J Hill; Terence A Ketter
Journal:  J Psychiatr Res       Date:  2008-06-25       Impact factor: 4.791

Review 5.  Bipolar and major depressive disorder: neuroimaging the developmental-degenerative divide.

Authors:  Jonathan Savitz; Wayne C Drevets
Journal:  Neurosci Biobehav Rev       Date:  2009-01-21       Impact factor: 8.989

6.  Expression analyses of the mitochondrial complex I 75-kDa subunit in early onset schizophrenia and autism spectrum disorder: increased levels as a potential biomarker for early onset schizophrenia.

Authors:  Regina Taurines; Johannes Thome; J Catharina Duvigneau; Sarah Forbes-Robertson; Liya Yang; Karin Klampfl; Jasmin Romanos; Sabine Müller; Manfred Gerlach; Claudia Mehler-Wex
Journal:  Eur Child Adolesc Psychiatry       Date:  2009-11-06       Impact factor: 4.785

Review 7.  Disorders of thought are severe mood disorders: the selective attention defect in mania challenges the Kraepelinian dichotomy a review.

Authors:  C Raymond Lake
Journal:  Schizophr Bull       Date:  2007-05-21       Impact factor: 9.306

8.  Metabolic brain pattern of sustained auditory discrimination.

Authors:  R M Cohen; W E Semple; M Gross; A C King; T E Nordahl
Journal:  Exp Brain Res       Date:  1992       Impact factor: 1.972

9.  Principal component and volume of interest analyses in depressed patients imaged by 99mTc-HMPAO SPET: a methodological comparison.

Authors:  Marco Pagani; Ann Gardner; Dario Salmaso; Alejandro Sánchez Crespo; Cathrine Jonsson; Hans Jacobsson; Greger Lindberg; Anna Wägner; Tore Hällström; Stig A Larsson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02-19       Impact factor: 9.236

10.  Neural models of schizophrenia.

Authors:  S Heckers
Journal:  Dialogues Clin Neurosci       Date:  2000-09       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.